Cannabis (medicinal) - Spasticity and muscle spasm

You are here : Home > Formulary Search > Cannabis (medicinal) - Spasticity and muscle spasm

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue

Formulations :

Oromucosal spray

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Documentation

Evidence Review

Sativex for spasticity in Multiple Sclerosis - Evidence Review - November 2021.pdf

Webpage

NHS England advice - Cannabis-based products for medicinal use

Information

Cancard information for GPs - Dec 2020

PAD Profile

ChemicalSubstance :

Cannabis (medicinal)

Indication :

Spasticity and muscle spasm

Group Name :

Keywords :

spasticity in multiple sclerosis, spasticity in MS, THC, cannabidiol, CBD, Cancard, Payment by Responder, MS , Sativex oromucosal spray, cannabis-based products for medicinal use, CBPM

Brand Names Include :

Sativex

Important Information :

For spasticity in MS. Specialist to prescribe for the first 12 weeks and determine response before transfer of care.

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Cannabis (medicinal) is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Spasticity and muscle spasm.

Committee Recommendations (2)

01 Nov 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

NHS England guidance to support clinicians on the prescribing of cannabis-based products for medicinal use:

https://www.england.nhs.uk/medicines-2/support-for-prescribers/cannabis-based-products-for-medicinal-use/

02 Mar 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee agree that Sativex for the treatment of spasticity in Multiple Sclerosis patients should be given a BLUE (no information sheet) traffic light status.

The specialist team will prescribe the first 12 weeks of treatment using the payment by responder scheme (3 vials free of charge), and will determine response to Sativex in line with the information in the licence [https://www.medicines.org.uk/emc/product/602], before transfer of care is requested.